Sana Biotechnology (NASDAQ:SANA) Price Target Cut to $6.00 by Analysts at Bank of America

Sana Biotechnology (NASDAQ:SANA) had its target price lowered by Bank of America from $7.00 to $6.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms also recently commented on SANA. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Rodman & Renshaw started coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $3.55 on Friday. Sana Biotechnology has a 52-week low of $2.61 and a 52-week high of $6.55. The company has a market capitalization of $1.06 billion, a P/E ratio of -4.67 and a beta of 2.16. The company has a 50-day simple moving average of $3.37 and a 200 day simple moving average of $3.45.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. As a group, equities analysts forecast that Sana Biotechnology will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Sana Biotechnology during the second quarter valued at approximately $58,196,000. Canada Pension Plan Investment Board acquired a new position in Sana Biotechnology in the 2nd quarter worth about $35,662,000. Vanguard Group Inc. raised its holdings in Sana Biotechnology by 19.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after buying an additional 1,517,474 shares during the last quarter. State Street Corp raised its stake in shares of Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after acquiring an additional 1,374,300 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Sana Biotechnology by 20.3% during the 4th quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock worth $16,763,000 after purchasing an additional 694,606 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Key Sana Biotechnology News

Here are the key news stories impacting Sana Biotechnology this week:

• Positive Sentiment: Bank of America lowered its price target to $6 from $7 but maintained a Buy rating. The revised target still implies substantial upside from recent trading levels, signaling confidence in Sana’s longer-term biotechnology potential. Benzinga article
• Positive Sentiment: A separate report described analysts as bullish on Sana Biotechnology and other healthcare stocks, adding to the favorable analyst backdrop. Analysts Are Bullish on Top Healthcare Stocks
• Neutral Sentiment: HC Wainwright’s revised FY2026 loss estimate improved to $0.54 per share from $0.56, but it remains below the broader consensus estimate of a $0.59 loss. The firm expects losses of $0.14 per share in both the third and fourth quarters of 2026.
• Negative Sentiment: HC Wainwright reduced its Q3 and Q4 2026 EPS forecasts to losses of $0.14 per share from $0.13, indicating somewhat higher expected near-term cash burn.
• Negative Sentiment: The firm also cut its FY2028, FY2029 and FY2030 EPS forecasts to losses of $0.62, $0.62 and $0.45 per share, respectively. These revisions suggest profitability may take longer to achieve and are likely the main reason for the stock’s weaker tone.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.